February 17, 2022
FDA accepts for priority review BMS’s Breyanzi as a second-line therapy for relapsed or refractory large B-cell lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics…